Breast cancer causes and treatment: where are we going wrong?
Author(s): Seymour CB | Mothersill C
Volume: 2013
Issue: default
Year: 2013




The incidence rate of female breast cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001–2008
Author(s): Alghamdi IG | Hussain II | Alghamdi MS | El-Sheemy MA
Volume: 2013
Issue: default
Year: 2013




Enhanced radiation response in radioresistant MCF-7 cells by targeting peroxiredoxin II
Author(s): Diaz AJG | Tamae D | Yen Y | Li JJ | Wang T
Volume: 2013
Issue: default
Year: 2013




Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
Author(s): Areepium N | Panomvana D | Rungwanonchai P | Sathaporn S | Voravud N
Volume: 2013
Issue: default
Year: 2013




Emerging targeted combinations in the management of breast cancer
Author(s): Lee RJ | Armstrong AC | Wardley AM
Volume: 2013
Issue: default
Year: 2013




Elevated preoperative serum cancer antigen 15.3 levels are associated with reduced disease-free survival: a single-institution experience
Author(s): Alsaeed EF | Abdulkarim H | Tunio MA
Volume: 2013
Issue: default
Year: 2013




Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment
Author(s): Kidd LR | Rogers EN | Yeyeodu ST | Jones DZ | Kimbro KS
Volume: 2013
Issue: default
Year: 2013




Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
Author(s): Abdel Kader Y | Spielmann M | El-Nahas T | Sakr A | Metwally H
Volume: 2013
Issue: default
Year: 2013




Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
Author(s): Saksena R | Wong ST
Volume: 2013
Issue: default
Year: 2013




Population-based service mammography screening: the Icelandic experience
Author(s): Sigurdsson K | Ólafsdóttir EJ
Volume: 2013
Issue: default
Year: 2013




Patients opting for breast reconstruction following mastectomy: an analysis of uptake rates and benefit
Author(s): Howard-McNatt MM
Volume: 2013
Issue: default
Year: 2013




Serum calcium levels, TRPM7, TRPC1, microcalcifications, and breast cancer using breast imaging reporting and data system scores
Author(s): Mandavilli S | Singh BB | Sahmoun AE
Volume: 2013
Issue: default
Year: 2012




Dormancy in breast cancer
Author(s): Banys M | Hartkopf AD | Krawczyk N | Kaiser T | Meier-Stiegen F | Fehm T | Neubauer H
Volume: 2012
Issue: default
Year: 2012




Implications for breast cancer dormancy in other areas of medicine
Author(s): Rameshwar P
Volume: 2012
Issue: default
Year: 2012




Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
Author(s): Machado M | Einarson TR
Volume: 2012
Issue: default
Year: 2012




Keeping an open mind: highlights and controversies of the breast cancer stem cell theory
Author(s): Shah M | Allegrucci C
Volume: 2012
Issue: default
Year: 2012




Therapeutic reduction mammoplasty in large-breasted women with cancer using superior and superomedial pedicles
Author(s): Denewer A | Shahatto F | Elnahas W | Farouk O | Roshdy S | Khater A | Hussein O | Teima S | Hafez M | Zidan S | Shams N | Kotb S
Volume: 2012
Issue: default
Year: 2012




Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy
Author(s): Abramson RG | Arlinghaus LR | Weis JA | Li X | Dula AN | Chekmenev EY | Smith SA | Miga MI | Abramson VG | Yankeelov TE
Volume: 2012
Issue: default
Year: 2012




Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance
Author(s): Yamamoto D | Tanaka K | Tsubota Y | Sueoka N | Shoji T | Kuwana K | Kwon AH
Volume: 2012
Issue: default
Year: 2012




Potential of afatinib in the treatment of patients with HER2-positive breast cancer
Author(s): Geuna E | Montemurro F | Aglietta M | Valabrega G
Volume: 2012
Issue: default
Year: 2012




Sonomammographic characteristics of invasive lobular carcinoma
Author(s): Kombar OR | Fahmy DM | Brown MV | Farouk O | El-Damshety O
Volume: 2012
Issue: default
Year: 2012




Targeting γ-secretase in breast cancer
Author(s): Han J | Shen Q
Volume: 2012
Issue: default
Year: 2012




Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
Author(s): Bauer M | Bryce J | Hadji P
Volume: 2012
Issue: default
Year: 2012




New developments in the treatment of HER2-positive breast cancer
Author(s): Nahta R
Volume: 2012
Issue: default
Year: 2012




Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
Author(s): Hurvitz SA | Kakkar R
Volume: 2012
Issue: default
Year: 2012




In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast
Author(s): Lee O | Ivancic D | Chatterton RT Jr | Rademaker AW | Khan SA
Volume: 2011
Issue: default
Year: 2011




The p53 breast cancer tissue biomarker in Indian women
Author(s): Patil V | Tayade M | Pingale S | Dalvi S | Rajekar R | Deshmukh H | Patil S | Singhai R
Volume: 2011
Issue: default
Year: 2011




Emerging role of brain metastases in the prognosis of breast cancer patients
Author(s): Hambrecht A | Jandial R | Neman J
Volume: 2011
Issue: default
Year: 2011




Breast reconstruction: current and future options
Author(s): Paul Jr H | Prendergast TI | Nicholson B | White S | Frederick WA
Volume: 2011
Issue: default
Year: 2011




Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Author(s): Menis J | Twelves C
Volume: 2011
Issue: default
Year: 2011




Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
Author(s): Schneider RE | Barakat AY | Pippen JE | Osborne CR
Volume: 2011
Issue: default
Year: 2011




Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
Author(s): Vogel VG
Volume: 2011
Issue: default
Year: 2011




Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
Author(s): Merriam PA | Sikov WM
Volume: 2011
Issue: default
Year: 2011




Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
Author(s): Chan VTC | Yeo W
Volume: 2011
Issue: default
Year: 2011




Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature
Author(s): Demichelis SO | Isla-Larrain MT | Cermignani L | Alberdi CG | Segal-Eiras A | Croce MV
Volume: 2011
Issue: default
Year: 2011




Does Veritas® play a role in breast reconstruction? a case report
Author(s): Borgognone A | Anniboletti T | De Vita F
Volume: 2011
Issue: default
Year: 2011




Psychiatric morbidity among Egyptian breast cancer patients and their partners and its impact on surgical decision-making
Author(s): El-Hadidy MA | Elnahas W | Hegazy MAF | Hafez MT | Refky B | Abdel Wahab KM
Volume: 2012
Issue: default
Year: 2012




A triple negative breast cancer: what it is not!
Author(s): Katakkar SB
Volume: 2012
Issue: default
Year: 2012




Potential clinical applications of halichondrins in breast cancer and other neoplasms
Author(s): Ortega V | Cortes J
Volume: 2012
Issue: default
Year: 2012




Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature
Author(s): Kyrgias G | Theodorou K | Zygogianni A | Tsanadis K | Zervoudis S | Tzitzikas | Koukourakis M
Volume: 2012
Issue: default
Year: 2012




Optimal management of bone metastases in breast cancer patients
Author(s): Wong MH | Pavlakis N
Volume: 2011
Issue: default
Year: 2011




Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women
Author(s): Patil AV | Bhamre RS | Singhai R | Tayade MB | Patil VW
Volume: 2011
Issue: default
Year: 2011




Cancer biomarker HER-2/neu in breast cancer in Indian women
Author(s): Singhai R | Patil VW | Patil AV
Volume: 2011
Issue: default
Year: 2011




Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
Author(s): Vinayak W Patil | Rajeev Singhai | Amit V Patil | et al
Volume: 2011
Issue: default
Year: 2011




Challenges in the development of future treatments for breast cancer stem cells
Author(s): Shyam A Patel | Anicia Ndabahaliye | Philip K Lim | et al
Volume: 2010
Issue: default
Year: 2010




p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells
Author(s): Anna C Cunningham-Edmondson | Steven K Hanks
Volume: 2009
Issue: default
Year: 2009




Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
Author(s): Matthew M Seavey | Yvonne Paterson
Volume: 2009
Issue: default
Year: 2009




New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
Author(s): Iain RJ Macpherson | TR Jeffry Evans
Volume: 2009
Issue: default
Year: 2009




Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
Author(s): Allan Lipton
Volume: 2011
Issue: default
Year: 2011




EGFR may couple moderate alcohol consumption to increased breast cancer risk
Author(s): Christopher P Mill | Julia A Chester | David J Riese II
Volume: 2009
Issue: default
Year: 2009



